A lactate-driven tag on a mitochondrial enzyme protected blood vessels in diabetic plaque models — in mice and endothelial cells
Edited by Samael A. Tejada, Founder & Editor-in-Chief
·Tip: press play, then lock your phone or switch apps — the article keeps reading.
A lactylation tag on the mitochondrial enzyme IDH2 (at lysine 272) keeps the enzyme active and alpha-ketoglutarate production up, protecting blood-vessel cells from mitochondrial damage in diabetic conditions; removing the tag worsened plaques in two mouse models, and alpha-KG supplementation mitigated plaque progression (Cell Death & Disease, November 5, 2026). The evidence is in mice and cultured endothelial cells; the human finding is elevated tag levels in diabetic plaques.
Lactate is usually cast as a waste product. Here it is the ink on a molecular sticky note: attach it to one site on a mitochondrial enzyme, and the enzyme keeps working, the vessel lining keeps its mitochondria intact, and diabetic plaques progress more slowly — at least in mice.
What exactly did the team find?
Endothelial IDH2 lactylation was already on this group's radar as cardiovascular-protective. This study pinned the effect to a single site — lysine residue 272 — and found the modification significantly elevated in diabetic plaques. Using an adenovirus to block lactylation at K272 in mouse aortic endothelial cells, they showed the tag maintains IDH2 enzymatic activity, ensuring sufficient biosynthesis of alpha-ketoglutarate and attenuating mitochondrial damage and endothelial dysfunction under hyperglycemic and hyperlipidemic conditions.
What happened in the animal models?
Two complementary models pointed the same way. In ApoE-knockout male mice given an adeno-associated virus that abrogates endothelial IDH2 lactylation, with diabetic plaques induced by streptozotocin, and in endothelial cell-specific IDH2-K272R knock-in male mice given AAV-PCSK9 plus streptozotocin, loss of K272 lactylation consistently exacerbated mitochondrial dysfunction and endothelial injury and promoted plaque formation and instability. The team also validated that exogenous supplementation of alpha-KG — the molecule IDH2 helps produce — effectively mitigates the progression of diabetic plaques.
Does this mean alpha-KG supplements treat diabetic artery disease?
No. The alpha-KG result is in a mouse model of diabetic plaque, reported without effect sizes in the abstract, and alpha-KG's role here is downstream of a specific enzyme modification in vessel-lining cells. Alpha-ketoglutarate is sold as a supplement ingredient (including in longevity formulas), but this study tested supplementation in mice, not people, and measured plaque progression in an induced model — not heart attacks, strokes or symptoms. The finding's value today is mechanistic: it identifies a druggable-looking control point (IDH2 lactylation) in diabetic vascular disease.
Frequently asked questions
What is lactylation?
Lactylation is a chemical modification in which a lactate-derived group is attached to a lysine residue on a protein, changing the protein's behavior. In this study, lactylation of the mitochondrial enzyme IDH2 at lysine 272 maintained the enzyme's activity.
What is alpha-ketoglutarate?
Alpha-ketoglutarate (alpha-KG) is a central intermediate of the Krebs cycle, produced in mitochondria with IDH2's help. In this study it was the downstream molecule through which IDH2 lactylation protected vessels, and supplementing it mitigated diabetic plaque progression in mice.
Were people treated in this study?
No. The human element is the observation that IDH2-K272 lactylation is elevated in diabetic plaques. All interventions were in cultured mouse endothelial cells and in two mouse models.
Where the evidence stands
- Established: IDH2 is a mitochondrial Krebs-cycle enzyme producing alpha-ketoglutarate, and endothelial mitochondrial dysfunction is a recognized contributor to diabetic atherosclerosis.
- Preliminary: The K272 lactylation mechanism: one group's work across endothelial cells and two mouse models, with consistent direction of effect but no effect sizes in the abstract and no human intervention data.
- Absent: Any human treatment evidence for IDH2 lactylation or alpha-KG supplementation in diabetic atherosclerosis.
Join the discussion
To get the conversation started: What questions does this story raise for you? Share them below — every comment is reviewed by our moderators before it appears.
Community discussion only — not medical advice. Every comment is reviewed by our moderators before it appears. Sign in with Google or a free Hyvor account to join in.